Bayer sues generic drug maker over erectile dysfunction drug

WILMINGTON, Del. — Bayer Pharma AG is suing generic drug maker Watson Pharmaceuticals Inc. for allegedly infringing two U.S. patents for the erectile dysfunction drug Staxyn, Bloomberg reported.

Bayer contends that Watson is planning to market a copy of Staxyn, which was approved in the U.S. in 2010, before the patent protections expire.

“Watson has acted with full knowledge” of the patents “without a reasonable basis for believing that it would not be liable for infringing,” Leverkusen, Germany-based Bayer said in a complaint filed today in federal court in Wilmington, Del.